13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
13-valent Pneumococcal Vaccine
Conditions
13-valent Pneumococcal Vaccine, Premature Birth, Immunization, Safety
Trial Timeline
Oct 1, 2010 → Jan 1, 2014
NCT ID
NCT01193335About 13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccine is a approved stage product being developed by Pfizer for 13-valent Pneumococcal Vaccine. The current trial status is completed. This product is registered under clinical trial identifier NCT01193335. Target conditions include 13-valent Pneumococcal Vaccine, Premature Birth, Immunization.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01964716 | Phase 3 | Completed |
| NCT01193335 | Approved | Completed |
| NCT00824850 | Phase 2 | Completed |
Competing Products
1 competing product in 13-valent Pneumococcal Vaccine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 13-valent pneumococcal conjugate vaccine | Pfizer | Phase 3 | 76 |